News

bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...

Offering will provide robust, standardised tools for research and drug discovery.

Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.

This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...

Statement from our CFO on the situation concerning SVB.

bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells

New advisors will provide important and independent guidance.